PL4233867T3 - Inhibitor PDE5 do zastosowania w leczeniu przedniej niedokrwiennej neuropatii nerwu wzrokowego - Google Patents

Inhibitor PDE5 do zastosowania w leczeniu przedniej niedokrwiennej neuropatii nerwu wzrokowego

Info

Publication number
PL4233867T3
PL4233867T3 PL22158443.6T PL22158443T PL4233867T3 PL 4233867 T3 PL4233867 T3 PL 4233867T3 PL 22158443 T PL22158443 T PL 22158443T PL 4233867 T3 PL4233867 T3 PL 4233867T3
Authority
PL
Poland
Prior art keywords
treatment
optic neuropathy
pde5 inhibitor
ischemic optic
anterior ischemic
Prior art date
Application number
PL22158443.6T
Other languages
English (en)
Inventor
Francesco Impagnatiello
Elena Bastia
Gael Ronsin
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Sa filed Critical Nicox Sa
Publication of PL4233867T3 publication Critical patent/PL4233867T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL22158443.6T 2022-02-24 2022-02-24 Inhibitor PDE5 do zastosowania w leczeniu przedniej niedokrwiennej neuropatii nerwu wzrokowego PL4233867T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22158443.6A EP4233867B1 (en) 2022-02-24 2022-02-24 Pde5 inhibitor for use in the treatment of anterior ischemic optic neuropathy

Publications (1)

Publication Number Publication Date
PL4233867T3 true PL4233867T3 (pl) 2026-02-09

Family

ID=80787134

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22158443.6T PL4233867T3 (pl) 2022-02-24 2022-02-24 Inhibitor PDE5 do zastosowania w leczeniu przedniej niedokrwiennej neuropatii nerwu wzrokowego

Country Status (9)

Country Link
US (1) US20250170131A1 (pl)
EP (1) EP4233867B1 (pl)
JP (1) JP2025505847A (pl)
CN (1) CN118742309A (pl)
CA (1) CA3244595A1 (pl)
ES (1) ES3045971T3 (pl)
PL (1) PL4233867T3 (pl)
TW (1) TW202342046A (pl)
WO (1) WO2023161314A1 (pl)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2317650T3 (es) 1996-10-28 2009-04-16 Senju Pharmaceutical Co., Ltd. Farmacos para mejorar trastornos circulatorios oculares.
IL137429A0 (en) 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
AU779991B2 (en) * 1999-08-10 2005-02-24 Board Of Regents, The University Of Texas System Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
US6462066B2 (en) 1999-12-02 2002-10-08 University Of South Florida Method and composition for treatment of ischemic neuronal reperfusion injury
US20020168424A1 (en) 2002-07-31 2002-11-14 Dr. Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma
US10159669B2 (en) 2010-03-02 2018-12-25 Ian H. Chan Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use
CN112566670B (zh) 2018-08-06 2024-11-12 尼科斯股份有限公司 一氧化氮释放第5型磷酸二酯酶抑制剂
ES2969139T3 (es) 2020-02-05 2024-05-16 Nicox Sa Composiciones para el tratamiento del glaucoma e hipertensión ocular
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof

Also Published As

Publication number Publication date
ES3045971T3 (en) 2025-12-01
EP4233867C0 (en) 2025-09-03
CN118742309A (zh) 2024-10-01
JP2025505847A (ja) 2025-02-28
TW202342046A (zh) 2023-11-01
EP4233867B1 (en) 2025-09-03
CA3244595A1 (en) 2023-08-31
WO2023161314A1 (en) 2023-08-31
EP4233867A1 (en) 2023-08-30
US20250170131A1 (en) 2025-05-29

Similar Documents

Publication Publication Date Title
IL327380A (en) Combinations of WX-001 or its derivatives with KRAS G12C inhibitor for use in cancer treatment
PE20220807A1 (es) Nuevos inhibidores de egfr
MX2021001952A (es) Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met.
IL297849B1 (en) Composition for use in the treatment of APOL1-related disease
SI4084778T1 (sl) Formulacije inhibitorja amorfne kinaze in načini njihove uporabe
SMT202300266T1 (it) Composti deuterati per l'uso nel trattamento del cancro
MX2021014175A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
IL278178A (en) Use of pilocarpine hydrochloride to treat eye disorder
MX2021010115A (es) Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda.
HUE069020T2 (hu) Eljárások Sjögren-szindróma kezelésére Bruton-féle tirozinkináz gátlószerének alkalmazásával
GB202416046D0 (en) Compounds of use in methods for the treatment or prohylaxis of a coronavirus infection or covid 19
IL321393A (en) CTPS1 inhibitors for use in the treatment of cancers with CTPS2 deficiency
IL298713B1 (en) Use of a phosphodiesterase 10 inhibitor to treat Tourette syndrome
PH12021551590A1 (en) Quinoline compounds as inhibitors of tam and met kinases
PL4482481T3 (pl) Związki do zastosowania w leczeniu dystrofinopatii
EP4233867C0 (en) PDE5 INHIBITOR FOR USE IN THE TREATMENT OF ANTERIOR ISCHEMIC OPTIC NEUROPATHY
GB201918413D0 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918410D0 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
IL309172A (en) Vulbanazine for use in the additional treatment of schizophrenia
GB202002299D0 (en) Agents for use in the treatment of tissue damage
GB202111866D0 (en) Prodrugs for use in the treatment of tissue damage
PL4146225T3 (pl) Związki metylotioniniowe do zastosowania w leczeniu hipoksemii
GB201918416D0 (en) Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
AU2023902805A0 (en) Combination for use in the treatment of glioma
HK40079285A (en) Agents for use in the treatment of tissue damage 2